Chronic myeloid leukemia and interferon-α: A study of complete cytogenetic responders

Blood

Volumn 98, Issue 10, 2001, Pages 3074-3081

  Bonifazi, Francesca ^a   De Vivo, Antonio ^a   Rosti, Gianantonio ^a   Guilhot, François ^a   Guilhot, Joëlle ^a   Trabacchi, Elena ^a   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a   Shepherd, Patricia C A ^a   Steegmann, Juan Luis ^a   Kluin Nelemans, Hanneke C ^a   Thaler, Josef ^a   Simonsson, Bengt ^a   Louwagie, Andries ^a   Reiffers, Josy ^a   Mahon, François Xavier ^a   Montefusco, Enrico ^a   Alimena, Giuliana ^a   Hasford, Joerg ^a   Richards, Sue ^a   Saglio, Giuseppe ^a   Testoni, Nicoletta ^a   Martinelli, Giovanni ^a   Tura, Sante ^a   Baccarani, Michele ^a,b   more..

^a Study and Report Committee of the European Study Group on Interferon in Chronic Myeloid Leukemia   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; HYDROXYUREA; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON;

ADULT; AGED; ARTICLE; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CHRONIC TOXICITY; CONTROLLED STUDY; CYTOGENETICS; DEMENTIA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EUROPE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 18144451171     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.3074     Document Type: Article

References (46)

1. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;93:3393-3899.
2. A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065-1069.
3. Alimena G, Morra E, Lazzarino M, et al. Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood. 1988;72:642-647.
4. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532-538.
5. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254-261.
6. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
7. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064-4077.
8. Allan NC, Richards SM, Shepherd CA, et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392-1397.
9. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
10. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood. 1998;91:2713-2721.
11. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616-1620.
12. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol. 1988;25;62-73.
13. McGlave P. Chronic leukemias. In: Beatty PG, ed. Clinical and managed care issues in blood and marrow transplantation for haematological diseases: report of a symposium. March 14, 1996, Washington, DC. Exp Hemat. 1997;25:1195-1208.
14. Gale RP, Hehlmann R, Zhang M-J, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood. 1998;91:1810-1819.
15. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
16. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087-1092.
17. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541-1548.
18. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective study of α-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. Haematologica. 1999:84:707-715.
19. Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow up of 71 patients observed in a single center. Leukemia. 1999;14:389-392.
20. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94:1517-1536.
21. Hehlmann R, Ansari H, Hasford J, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol. 1997;97:76-85.
22. The German and Italian Chronic Myeloid Leukemia Study Groups. Interferon-α and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and the German chronic myeloid leukemia trials with interferon-α. Blood. 1996;87:5384-5391.
23. The Italian Cooperative Study Group on Chronic Myeloid leukemia and the Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol. 1999;17:1858-1868.
24. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62-66.
25. Chomel J-C, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogenic bone marrow transplantation. Blood. 2000;95:404-409.
26. Martinelli G, Testoni N, Amabile M, et al. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy. Bone Marrow Transplant. 2000;25:729-736.
27. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
28. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850-858.
29. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223-229.
30. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in good risk chronic granulocytic leukemia. Blood. 1984;63:789-799.
31. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient; II, analysis and examples. Br J Cancer. 1977;35:1-39.
33. Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood. 1993;82:2975-2984.
34. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994;121:736-744.
35. Montastruc M, Mahon F, Faberes C, et al. Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors. Leukemia. 1995;9:1997-2002.
36. Thaler J, Gastl G, Fluckinger T, et al. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Ann Hematol. 1996;72:349-355.
37. Mahon FX, Fabères C, Pueyo S, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood. 1998;92:4059-4065.
38. Steegmann JL, Odriozola J, Rodriguez-Salvanes F, et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica. 1999;84:978-87.
39. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 1997;82:478-495.
40. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
41. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Chronic myeloid leukemia, BCR/ABL transcript, response to α-interferon and survival. Leukemia. 1995;9:1648-1652.
42. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-2384.
43. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999;93:2755-2759.
44. Goldman JM, Kaeda JS, Cross NC, Hochhaus A, Hehlmann R. Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease [letter]. Blood. 1999;94:1484-1486.
45. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making [letter]. Blood. 1999;94:1486-1487.
46. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? [letter, response]. Blood. 1999;94:1487-1488.